These two patents, one granted in Canada and one in the US, cover formulations comprising any one or any combination of herbal extracts of herbaceous plants selected from the group consisting of damiana, blue lotus, mullein, lobelia, peppermint, spearmint, catnip, thyme, sage, wild dagga, lavender, rosemary, salvia divinorum, basil, lemon balm, hops, yerba mate, calea zacatechichi, chamomile, ashwagandha eucalyptus, passion flower, St John’s wart, valerian, astragalus, avena sativa, kinnikinnick, cacao, chago, , cinnamon, nutmeg, mace, cordyceps, Don Quai, Gotu Kola, ginger root, ginseng, green tea, kava, maca, moringa leaf, mullein, sacred pink lotus, red raspberry, rhodiola, rooibos, tong kat ali, vanilla, yohimbine, garlic, turmeric, nutmeg, capsaicin, rosemary, cannabis, coniferous trees, yew bush, willow tree, aspen tree, blood root, opium poppy, atropa belladonna, strychnine, vinca rosea, coffee plant, cacao tree and beans (chocolate), coca plant (cocaine), nicotinaa tabacum, camelia sinensis, monkshood, castor oil, henbane, Calabar bean, digitalis sp, autumn crocus, peyote, amanita, orange, lemon, and any other known herbaceous plants which produce known agents having useful medicinal, pharmacological, physiological, beneficial, sensory or other perceived measurable effects on humans. They also describe how to create an herbal formulation such as cannabinoids, opioids and St. John’s wart for chronic pain relief without causing overdose death.